These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 27529510)

  • 1. A Double-Blind, Placebo Controlled, Randomized Phase 1 Cross-Over Study with ALLN-177, an Orally Administered Oxalate Degrading Enzyme.
    Langman CB; Grujic D; Pease RM; Easter L; Nezzer J; Margolin A; Brettman L
    Am J Nephrol; 2016; 44(2):150-8. PubMed ID: 27529510
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ALLN-177, oral enzyme therapy for hyperoxaluria.
    Lingeman JE; Pareek G; Easter L; Pease R; Grujic D; Brettman L; Langman CB
    Int Urol Nephrol; 2019 Apr; 51(4):601-608. PubMed ID: 30783888
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Designer probiotic Lactobacillus plantarum expressing oxalate decarboxylase developed using group II intron degrades intestinal oxalate in hyperoxaluric rats.
    Paul E; Albert A; Ponnusamy S; Mishra SR; Vignesh AG; Sivakumar SM; Sivasamy G; Sadasivam SG
    Microbiol Res; 2018 Oct; 215():65-75. PubMed ID: 30172310
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Prospective, Double-Blind, Randomized, Placebo-Controlled, Crossover Study Using an Orally Administered Oxalate Decarboxylase (OxDC).
    Quintero E; Bird VY; Liu H; Stevens G; Ryan AS; Buzzerd S; Klimberg IW
    Kidney360; 2020 Nov; 1(11):1284-1290. PubMed ID: 35372879
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized Placebo-Controlled Trial of Reloxaliase in Enteric Hyperoxaluria.
    Lieske JC; Lingeman JE; Ferraro PM; Wyatt CM; Tosone C; Kausz AT; Knauf F
    NEJM Evid; 2022 Jul; 1(7):EVIDoa2100053. PubMed ID: 38319254
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diet, but not oral probiotics, effectively reduces urinary oxalate excretion and calcium oxalate supersaturation.
    Lieske JC; Tremaine WJ; De Simone C; O'Connor HM; Li X; Bergstralh EJ; Goldfarb DS
    Kidney Int; 2010 Dec; 78(11):1178-85. PubMed ID: 20736987
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized, controlled trial of lactic acid bacteria for idiopathic hyperoxaluria.
    Goldfarb DS; Modersitzki F; Asplin JR
    Clin J Am Soc Nephrol; 2007 Jul; 2(4):745-9. PubMed ID: 17699491
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The urinary response to an oral oxalate load in recurrent calcium stone formers.
    Krishnamurthy MS; Hruska KA; Chandhoke PS
    J Urol; 2003 Jun; 169(6):2030-3. PubMed ID: 12771711
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dietary treatment of urinary risk factors for renal stone formation. A review of CLU Working Group.
    Prezioso D; Strazzullo P; Lotti T; Bianchi G; Borghi L; Caione P; Carini M; Caudarella R; Ferraro M; Gambaro G; Gelosa M; Guttilla A; Illiano E; Martino M; Meschi T; Messa P; Miano R; Napodano G; Nouvenne A; Rendina D; Rocco F; Rosa M; Sanseverino R; Salerno A; Spatafora S; Tasca A; Ticinesi A; Travaglini F; Trinchieri A; Vespasiani G; Zattoni F;
    Arch Ital Urol Androl; 2015 Jul; 87(2):105-20. PubMed ID: 26150027
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Urinary lithogenic risk profile in recurrent stone formers with hyperoxaluria: a randomized controlled trial comparing DASH (Dietary Approaches to Stop Hypertension)-style and low-oxalate diets.
    Noori N; Honarkar E; Goldfarb DS; Kalantar-Zadeh K; Taheri M; Shakhssalim N; Parvin M; Basiri A
    Am J Kidney Dis; 2014 Mar; 63(3):456-63. PubMed ID: 24560157
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1.
    Garrelfs SF; Frishberg Y; Hulton SA; Koren MJ; O'Riordan WD; Cochat P; Deschênes G; Shasha-Lavsky H; Saland JM; Van't Hoff WG; Fuster DG; Magen D; Moochhala SH; Schalk G; Simkova E; Groothoff JW; Sas DJ; Meliambro KA; Lu J; Sweetser MT; Garg PP; Vaishnaw AK; Gansner JM; McGregor TL; Lieske JC;
    N Engl J Med; 2021 Apr; 384(13):1216-1226. PubMed ID: 33789010
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of enteric hyperoxaluria with calcium-containing organic marine hydrocolloid.
    Lindsjö M; Fellström B; Ljunghall S; Wikström B; Danielson BG
    Lancet; 1989 Sep; 2(8665):701-4. PubMed ID: 2570957
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of Oxalobacter formigenes to reduce urinary oxalate in primary hyperoxaluria.
    Hoppe B; Groothoff JW; Hulton SA; Cochat P; Niaudet P; Kemper MJ; Deschênes G; Unwin R; Milliner D
    Nephrol Dial Transplant; 2011 Nov; 26(11):3609-15. PubMed ID: 21460356
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hyperoxaluria is reduced and nephrocalcinosis prevented with an oxalate-degrading enzyme in mice with hyperoxaluria.
    Grujic D; Salido EC; Shenoy BC; Langman CB; McGrath ME; Patel RJ; Rashid A; Mandapati S; Jung CW; Margolin AL
    Am J Nephrol; 2009; 29(2):86-93. PubMed ID: 18698135
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral calcium supplement decreases urinary oxalate excretion in patients with enteric hyperoxaluria.
    Takei K; Ito H; Masai M; Kotake T
    Urol Int; 1998; 61(3):192-5. PubMed ID: 9933846
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduction of oxaluria after an oral course of lactic acid bacteria at high concentration.
    Campieri C; Campieri M; Bertuzzi V; Swennen E; Matteuzzi D; Stefoni S; Pirovano F; Centi C; Ulisse S; Famularo G; De Simone C
    Kidney Int; 2001 Sep; 60(3):1097-105. PubMed ID: 11532105
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant Lactobacillus plantarum expressing and secreting heterologous oxalate decarboxylase prevents renal calcium oxalate stone deposition in experimental rats.
    Sasikumar P; Gomathi S; Anbazhagan K; Abhishek A; Paul E; Vasudevan V; Sasikumar S; Selvam GS
    J Biomed Sci; 2014 Aug; 21(1):86. PubMed ID: 25175550
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oxalate-degrading microorganisms or oxalate-degrading enzymes: which is the future therapy for enzymatic dissolution of calcium-oxalate uroliths in recurrent stone disease?
    Peck AB; Canales BK; Nguyen CQ
    Urolithiasis; 2016 Feb; 44(1):45-50. PubMed ID: 26645869
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of absence of intestinal oxalate degrading bacteria with urinary calcium oxalate stone formation.
    Mikami K; Akakura K; Takei K; Ueda T; Mizoguchi K; Noda M; Miyake M; Ito H
    Int J Urol; 2003 Jun; 10(6):293-6. PubMed ID: 12757596
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of a probiotic to decrease enteric hyperoxaluria.
    Lieske JC; Goldfarb DS; De Simone C; Regnier C
    Kidney Int; 2005 Sep; 68(3):1244-9. PubMed ID: 16105057
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.